Table of Contents
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now. But what if we could predict which patients will respond to immunotherapy before treatment even begins?
Nucleai is building the spatial biology operating system that makes this possible.
Their AI platform analyzes tumor tissue at single-cell resolution, mapping the spatial relationships between immune and cancer cells to uncover predictive biomarkers invisible to the human eye.
Notably:
- They are already partnered with 15+ pharma companies, alongside Mayo Clinic and Bio-Techne
- They recently powered a landmark Nature Communications study linking tumor spatial organization to immunotherapy response in lung cancer - and identified immune cell interactions that predict survival in melanoma.
At JPM 2026, Onyx sat down with CEO Avi Veidman to find out more.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW - a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea - AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Comments